Equity · Healthcare
EXEL
NASDAQExelixis (EXEL)
The line runs 54.55 USD on 24 August through 59.90 USD on 9 October, on a scale from 54 to 60. Days the market did not trade hold the previous close, flat.
- Market cap
- 14.6B USD
- P/E (TTM)
- 17.9
- Revenue, year to Jan 2026
- 2.3B USD
- EPS, diluted, year to Jan 2026
- 2.78 USD
- 52-week range
- 34.54 USD – 59.90 USD
- Avg volume
- 99.2K
as of Oct 9, 2026
Have Exelixis (EXEL) insiders bought or sold shares recently?
EXEL's newest Form 4 filing is dated 10 August 2026: none in the last 90 days.
| Reported | Insider | Type | Shares | Value |
|---|---|---|---|---|
| 10 Aug 2026 | Beckerle Mary CDirector | Sell | 9,812 | 527K USD |
| 01 Jun 2026 | Eckhardt Sue GailDirector | Sell | 9,812 | 492K USD |
| 01 Jun 2026 | WYSZOMIERSKI JACK LDirector | Sell | 3,925 | 198K USD |
| 26 May 2026 | Aftab DanaEVP, Research and Development | Sell | 43,451 | 2.2M USD |
| 20 May 2026 | Haley Patrick J.EVP, Commercial | Sell | 32,110 | 1.6M USD |
| 18 May 2026 | Hefti BrendaSVP and General Counsel | Sell | 6,625 | 333K USD |
| 18 May 2026 | Senner Christopher J.EVP and CFO | Sell | 34,901 | 1.7M USD |
| 07 May 2026 | Beckerle Mary CDirector | Sell | 7,712 | 374K USD |
| 07 May 2026 | POSTE GEORGEDirector | Sell | 60,000 | 2.7M USD |
| 07 May 2026 | Freire Maria CDirector | Sell | 20,634 | 949K USD |
| 24 Feb 2026 | Aftab DanaEVP, Research and Development | Sell | 47,918 | 2.1M USD |
| 19 Feb 2026 | Aftab DanaEVP, Research and Development | Sell | 29,873 | 1.3M USD |
| Bought | 1 open-market purchase | 27,532 | $1.19M | |
| Sold | 26 open-market sales | 943,605 | $42.24M |
Showing the 12 most recent of 27 open-market trades in this window. The figures above count all of them.
51 other filings: grants, exercises, tax withholding and transfers, not trades
| Reported | Insider | Type | Shares | Value |
|---|---|---|---|---|
| 27 May 2026 | Beckerle Mary CDirector | Award | 8,367 | |
| 27 May 2026 | POSTE GEORGEDirector | Award | 8,367 | |
| 27 May 2026 | WYSZOMIERSKI JACK LDirector | Award | 8,367 | |
| 27 May 2026 | Oliver BobDirector | Award | 8,367 | |
| 27 May 2026 | Freire Maria CDirector | Award | 8,367 | |
| 27 May 2026 | Smith JulieDirector | Award | 8,367 | |
| 27 May 2026 | Eckhardt Sue GailDirector | Award | 8,367 | |
| 27 May 2026 | Heyman Tomas J.Director | Award | 8,367 | |
| 27 May 2026 | PAPADOPOULOS STELIOSDirector | Award | 8,367 | |
| 18 May 2026 | MORRISSEY MICHAELPresident and CEO | Gift | 248,094 | |
| 15 May 2026 | Aftab DanaEVP, Research and Development | Tax withheld | 30,578 | 1.6M USD |
| 15 May 2026 | Hefti BrendaSVP and General Counsel | Tax withheld | 6,411 | 328K USD |
Showing the 12 most recent of 51 compensation filings in this window. The figures above count all of them.
Which funds hold Exelixis (EXEL)?
12 of the 45 institutional funds we track reported a Exelixis position for the quarter ended 30 Sep 2026 — a combined 1.9B USD; the latest of those filings landed 16 Nov 2026.
| Fund | Position | Shares | Value | Shares q/q |
|---|---|---|---|---|
| Renaissance Technologies | Held (±25%) | 12,792,693 | 747.2M USD | −4.7% |
| AQR Capital Management | Held (±25%) | 9,607,499 | 561.2M USD | −12.8% |
| D. E. Shaw & Co. | Held (±25%) | 5,599,137 | 327.0M USD | +0.9% |
| Two Sigma Investments | Held (±25%) | 3,252,847 | 190.0M USD | −22.7% |
| Man Group | Held (±25%) | 380,886 | 22.2M USD | −16.6% |
| Millennium Management | Trimmed | 354,857 | 20.7M USD | −70.9% |
| Bridgewater Associates | Held (±25%) | 328,588 | 19.2M USD | −18.0% |
| Fisher Asset Management | Held (±25%) | 214,045 | 12.5M USD | +9.4% |
| Marshall Wace | Trimmed | 113,538 | 6.6M USD | −86.3% |
| Tudor Investment Corp | Added | 111,760 | 6.5M USD | +2,312.8% |
Showing the 10 largest of 12 reported positions. The figures above count all of them.
What has been filed or recorded for Exelixis (EXEL)?
The filings we hold for Exelixis, newest first: 1 fails-to-deliver day, 6 quarterly earnings reports, 2 annual reports and 5 reported financial figures, the latest dated 09 Oct 2026. No next earnings date is announced in SEC filings yet.
| And | ||||
|---|---|---|---|---|
| 09 Oct 2026 | Fails to deliver | Shares failed to deliver | 434 shares | 26K USD notional · <0.001% of shares out |
| 02 Oct 2026 | Quarterly earnings | Q3 2026 reported | EPS 0.85 USD | |
| 02 Oct 2026 | Financials | Total assets | 2.5B USD | at period end |
| 02 Oct 2026 | Financials | Total equity | 1.8B USD | at period end |
| 03 Jul 2026 | Quarterly earnings | Q2 2026 reported | EPS 0.82 USD | |
| 03 Apr 2026 | Quarterly earnings | Q1 2026 reported | EPS 0.79 USD | |
| 02 Jan 2026 | Annual report | FY 2025 reported | EPS 2.78 USD | |
| 02 Jan 2026 | Financials | Revenue | 2.3B USD | fiscal year |
| 02 Jan 2026 | Financials | Net income | 782.6M USD | fiscal year |
| 02 Jan 2026 | Financials | Diluted EPS | 2.78 USD | fiscal year |
| 03 Oct 2025 | Quarterly earnings | Q3 2025 reported | EPS 0.69 USD | |
| 04 Jul 2025 | Quarterly earnings | Q2 2025 reported | EPS 0.65 USD | |
| 04 Apr 2025 | Quarterly earnings | Q1 2025 reported | EPS 0.55 USD | |
| 03 Jan 2025 | Annual report | FY 2024 reported | EPS 1.76 USD |
What do people ask about Exelixis (EXEL)?
What did Exelixis shares close at?59.90
Exelixis closed at 59.90 USD on 9 Oct 2026, up 1.53% on the close before. That is the end-of-day price from Finazon, not a live quote.
What is Exelixis’ market cap?14.6B
Exelixis is worth 14.6B USD by market value as of 9 Oct 2026, which is the share price times the shares on issue from its SEC filings.
What is Exelixis’ P/E ratio?17.9
Exelixis has a price-to-earnings ratio of 17.9, as of 9 Oct 2026: the share price divided by what the company earned per share over the last four reported quarters. A higher number means the market pays more for each dollar of earnings.
What is Exelixis’ revenue?2.3B
Exelixis reported revenue of 2.3B USD for the year ended 2 Jan 2026, as filed with the SEC. See Filings
Have Exelixis insiders bought or sold shares recently?
No Exelixis insider has filed a Form 4 in the last 90 days; the most recent filing we hold is dated 10 Aug 2026 (SEC Form 4). See Insiders
Which funds own Exelixis?12 of 45
12 of the 45 funds we track reported a Exelixis position for the quarter ended 30 Sep 2026, per their SEC Form 13F filings. The largest reported positions were Renaissance Technologies, AQR Capital Management and D. E. Shaw & Co. See Funds
When did Exelixis last report earnings?0.85
Exelixis last reported earnings on 2 Oct 2026 for Q3 2026, with EPS of 0.85 USD; no next date is announced in SEC filings yet. See Filings

Answers are generated from the live figures on this page — Reddit crowd data, SEC filings and open company records — and update as the data does.
References
- Finazonprior-day close, indicative (IEX-derived, not the official close), most closes dollar-rounded at the source
- TradingViewthe price chart widget, drawn by TradingView from their own data
- SEC EDGARForm 4 filings (insider transactions)
- SEC EDGAR13F filings
- SECSEC fails-to-deliver (CNS) data
- SEC EDGARXBRL company facts, latest period ended 02 Oct 2026
- SEC EDGARreported earnings figures and scheduled report dates
- SEC EDGARValuation computed from SEC EDGAR filings
- SEC filingAbout text: the company's latest annual report filed with the SEC (Business section), summarised in our own words